ライフサイエンスコーパス: tumor-specific

1 lls, suggesting that responding cells may be tumor specific.

2 cell death both in vitro and in vivo through tumor-specific (1) O2 generation and subsequent ROS medi

3 particles demonstrated orthotopic pancreatic tumor specific accumulation compared to liver or kidney

4 promoter deposition correlated strongly with tumor-specific activation and repression of transcriptio

5 ta-24-RGD, Delta-24-RGDOX exhibited superior tumor-specific activation of lymphocytes and proliferati

6 netic heterogeneity among CTCs and indicates tumor-specific active epigenetic regulation of EMT-assoc

7 nanocarriers and/or affinity targeting with tumor-specific affinity ligands, such as tumor homing pe

8 ng to new ways to target this class of ideal tumor-specific Ags and could allow the application of im

9 T cells engineered to express a tumor-specific alphabeta T cell receptor (TCR) mediate a

10 The majority of tumor-specific alterations in ovarian cancers were prese

11 argets were identified as both ancestral and tumor-specific alterations.

12 emotherapy (nATC) delivery strategy in which tumor specific and clinically relevant antibodies (ritux

13 ure cancer immunotherapies, because they are tumor specific and have been shown to elicit cytotoxic T

14 molecular weight (LMW-E) isoforms, which are tumor-specific and accumulate in the cytoplasm because t

15 Tumor-specific and cell-autonomous activation of the tum

16 tic effect of entolimod and establishment of tumor-specific and durable immune memory.

17 ikely due to the simultaneous recognition of tumor-specific and host-restricted minor histocompatibil

18 CI of rGel/EGF was further shown as a highly tumor-specific and potent modality in vivo, with growth

19 fusion partners, most notably EWSR1, are not tumor specific (and may, in fact, also be found in benig

20 er vaccination, resulting in an efficacious, tumor-specific, and long-lasting therapeutic effect.

21 Therapeutic concepts exploiting tumor-specific antibodies are often established in pre-c

22 l radiotherapy and intratumoral injection of tumor-specific antibodies, arising in part from enhanced

23 with intratumoral injection of an IL2-linked tumor-specific antibody (termed here an immunocytokine),

24 CD47 blockade alone or in combination with a tumor-specific antibody fails to generate antitumor immu

25 dose of IL-2 immunocytokine synergized with tumor-specific antibody to significantly enhance therape

26 ), also known as ETAA16, was identified as a tumor-specific antigen in the Ewing family of tumors.

27 of the quaternary structure of the secreted tumor-specific antigen reduces its immunogenicity.

28 protein is a surprisingly broad, yet highly tumor-specific, antigen.

29 ow that host T cells properly primed against tumor-specific antigens after conventional treatment, wh

30 ulatory processes, which cause expression of tumor-specific antigens and tumor-associated antigens (T

31 CD8(+) T cells recognizing tumor-specific antigens are detected in cancer patients

32 apy in which cytotoxic T cells (CTLs) target tumor-specific antigens complexed to MHC-I molecules has

33 tumor cells produced hs2dAb directed against tumor-specific antigens further highlighting the potenti

34 Enhanced cytosolic bioavailability of tumor-specific antigens improves access to human leukocy

35 mal tissues, and there is a paucity of truly tumor-specific antigens shared across tumor types.

36 remains limited by the rarity of targetable tumor-specific antigens, tumor-mediated immune suppressi

37 the melanoma antigen gene (MAGE-I) family of tumor-specific antigens.

38 8+ cytotoxic T cell responses against murine tumor-specific antigens.

39 on that does not depend on identification of tumor-specific antigens.

40 hermore, we demonstrated evidence of durable tumor-specific antitumor immunity.

41 itivity, and the mechanism of statin-induced tumor-specific apoptosis remains unclear.

42 Cs, and that TRAIL-expressing hADSCs induced tumor-specific apoptosis.

43 oversial but consists largely of a selective tumor-specific approach to surgical resection.

44 pMHC multimer staining of tumor-specific, autoimmune, or MHC class II-restricted T

45 vation with low-dose warfarin, or with other tumor-specific Axl-targeting agents, blocks the progress

46 eavy chain of the antibody) fused to iRGD, a tumor-specific binding peptide with high permeability.

47 Our hypothesis states that tumor-specific biomarkers such as entropy should be corr

48 s been shown to be a rich source of putative tumor-specific biomarkers.

49 These tumor-specific blood vessels are characterized by a deve

50 L1 targeting relies upon the reactivation of tumor-specific but functionally impaired PD-1(+) T cells

51 Tumor-specific CD4 and CD8 T cells could be metabolicall

52 r, our findings provide a novel mechanism of tumor-specific CD4 T cell activation and will be useful

53 imited by tolerance pathways that inactivate tumor-specific CD4 Th cells.

54 tial activation and overall expansion of the tumor-specific CD4(+) T cell population.

55 MHC class II molecules, which by attracting tumor-specific CD4(+) T cells elicit a local inflammator

56 mmatory cytokines and cytotoxic molecules in tumor-specific CD4(+) T cells.

57 Notably, we found that tumor-specific CD4(+) T-cell responses were dominated by

58 tioning allowed adoptively transferred naive tumor-specific CD4+ T cells to undergo effector differen

59 In view of the accepted role of tumor-specific CD4+ T-cell responses in tumor control, w

60 n tumor-bearing mice can enhance NK cell and tumor-specific CD8 T cell numbers.

61 etion studies reveal contributions from both tumor-specific CD8 T cells and NK cells in control of tu

62 T with a pathogen, we genetically engineered tumor-specific CD8 T cells in vitro with a second T-cell

63 Notably, although tumor-specific CD8 T lymphocytes expanded robustly after

64 Tumor-specific CD8(+) cytotoxic T lymphocytes (CTLs) pla

65 the activation and differentiation of naive tumor-specific CD8(+) T (TST) cells after tumor initiati

66 rammed death-1 (PD-1) and its ligands hamper tumor-specific CD8(+) T cell (TCD8) responses, and PD-1-

67 , explaining their reduced ability to induce tumor-specific CD8(+) T cell priming.

68 -presenting cells and activate them to prime tumor-specific CD8(+) T cell responses.

69 ion that regulates the functional avidity of tumor-specific CD8(+) T cells and can be manipulated to

70 KKbeta augmented the frequency of functional tumor-specific CD8(+) T cells and improved tumor control

71 s (DC) that are crucial for the induction of tumor-specific CD8(+) T cells capable of mediating durab

72 , we compared genome-wide mRNA expression of tumor-specific CD8(+) T cells from the tumor and periphe

73 ld alter the CpG-mediated differentiation of tumor-specific CD8(+) T cells into CD127(low)KLRG1(high)

74 we addressed the need to identify and select tumor-specific CD8(+) T cells of highest avidity, which

75 deficient mice, whereas adoptive transfer of tumor-specific CD8(+) T cells restored combinatorial eff

76 ated with increases in the systemic level of tumor-specific CD8(+) T cells, and an increased ratio of

77 , increasing the quantity and the quality of tumor-specific CD8(+) T cells.

78 depleted CCR2(+) Treg, enhancing priming of tumor-specific CD8(+) T cells.

79 tact antigens to the lymph nodes and priming tumor-specific CD8(+) T cells.

80 DCs and pDCs mature and are able to activate tumor-specific CD8(+) T cells.

81 ma signaling, led to impaired recognition by tumor-specific CD8(+) T cells.

82 t dendritic cells (DC) could further enhance tumor-specific CD8(+) T-cell polyfunctionality in vivo w

83 factors influencing the effector function of tumor-specific CD8+ T cells is covered.

84 Long-term persistence of ex vivo-expanded tumor-specific CD8+ T effector clones has been reported

85 SF35 in subcutaneous B16 melanomas generates tumor-specific, CD8(+) T cells that express PD-1 and sup

86 s, Cyrillic cells (DCs) and thus stimulate a tumor-specific, CD8+ cytotoxic T cell response.

87 Notably, JA induced significant tumor-specific cell death and a significant increase in

88 er the attractive therapeutic combination of tumor-specific cell lysis together with immune stimulati

89 omas express a functionally active and truly tumor-specific cell-surface product, the variable region

90 k of fast-growing tumor but also transfer of tumor-specific cells that maintain an ability for self-r

91 n this issue of Cell, two articles show that tumor-specific changes in HLA-mediated antigen presentat

92 rd ROS by coexpressing catalase along with a tumor specific chimeric Ag receptor (CAR) to increase th

93 The penetration was tumor-specific, circulation-independent, and mediated by

94 appealing methods to improve the potency of tumor-specific clinical grade T cells.

95 nfrared labeled ErbB2 peptide that generates tumor-specific contrast in human xenograft breast tumors

96 PKCiota gene PRKCI is targeted for frequent tumor-specific copy number gain (CNG) in both lung squam

97 tratumoral TNF-alpha, which is indicative of tumor-specific CTL activity.

98 E-cadherin-Fc of CD103 integrin expressed on tumor-specific CTL clones promotes phosphorylation of Px

99 tumor-infiltrating lymphocytes and CD103(+) tumor-specific CTL clones.

100 Labeled tumor-specific CTLs accumulated in the tumor (4.6% on da

101 t cancer requires simultaneous generation of tumor-specific CTLs and curtailment of tumor immunosuppr

102 s, immunotherapy with just a small number of tumor-specific CTLs in which miR-23a was inhibited robus

103 a sublethal dose to enhance the efficacy of tumor-specific CTLs, and these ceramide analogs hold gre

104 noma development, and HSP70 inhibitors exert tumor-specific cytotoxic activity in cancer.

105 date have focused on transfer of autologous tumor-specific cytotoxic CD8(+) T cells; however, the po

106 ated distant tumors by generating a systemic tumor-specific cytotoxic T cell response.

107 itic cell vaccines, and adoptive transfer of tumor-specific cytotoxic T cells and natural killer cell

108 lammation and, eventually, the activation of tumor-specific cytotoxic T cells, their recruitment into

109 In particular, DTA-1-induced IL-9 promoted tumor-specific cytotoxic T lymphocyte (CTL) responses by

110 infiltrating leukocytes in tumors, including tumor-specific cytotoxic T lymphocytes (CTL), is altered

111 phorylation of GAB1 and demonstrated potent, tumor-specific cytotoxicity against MDA-MB-231 and T47D

112 We determined that tumor-specific cytotoxicity of the poliovirus/rhinovirus

113 non-tumor cells as well as the existence of tumor-specific DAMPs.

114 ng, it should be possible to integrate large tumor-specific datasets of varied types and effectively

115 uncovered peaks that coincide precisely with tumor-specific decrease of DNA methylation at 200 loci,

116 ivery of nanoparticles, we examined enhanced tumor-specific delivery of amphiphile-CpG, an albumin-bi

117 velopment of new tumor-imaging probes and in tumor-specific delivery of appropriately designed chemot

118 Taken together, we identify tumor-specific dependence on NOX2-driven mitochondrial t

119 Furthermore, tumor-specific disruption of Notch signaling may overcom

120 TPP might also be a promising platform for tumor-specific drug delivery and other Hsp70-based targe

121 nefits beyond tumoricidal effects to harness tumor-specific, durable, and systemic antitumor immunity

122 d by a lack of cell surface markers defining tumor-specific dysfunctional TILs, and PD-1 alone is not

123 s tissue specific editing events including 4 tumor-specific edits and 3 normal-specific edits in the

124 ized IL-2c infusion drastically improves the tumor-specific effector CD8 T cell response.

125 mTECs simultaneously limit the generation of tumor-specific effector T cells by expressing tumor self

126 hymic deletion and that persistence of these tumor-specific effector T cells promoted increased host

127 attractive strategy to increase the pool of tumor-specific effector T cells.

128 mmune tolerance by allowing for expansion of tumor-specific effectors ex vivo.

129 port that freshly isolated subpopulations of tumor-specific endothelial cells (TEC) from a spontaneou

130 To identify tumor-specific endothelial markers, we performed a micro

131 recruited by the EWS-FLI1 fusion protein to tumor-specific enhancers and contributes to target gene

132 Tumor-specific enhancers and superenhancers that are elu

133 ce suggests that tumors express immunogenic, tumor-specific epitopes generated from the same mutation

134 ike method to estimate mutation-specific and tumor-specific event rates concurrently with tree recons

135 odulatory gene circuit platform that enables tumor-specific expression of immunostimulators, which co

136 rvival, at least in part, by stabilizing the tumor-specific expression of PGC1beta.

137 Expression of SPZ1 exhibited a tumor-specific expression pattern and a high correlation

138 in normal parenchyma of the testis, implying tumor-specific expression.

139 -seq datasets to identify mRNA isoforms with tumor-specific expression.

140 sicle secretion, suggesting that identifying tumor-specific extracellular vesicle proteins in plasma

141 led to examine the impact of oxaliplatin and tumor-specific factors on the time course of recurrence

142 ng of peritoneal cavity organs; however, the tumor-specific factors that allow ovarian cancer cells t

143 Patient demographic characteristics and tumor-specific features may provide predictive informati

144 Recommendations On the basis of tumor-specific findings and competing risks of mortality

145 etely neutralized by adoptively transferring tumor-specific Foxp3(+) T cells.

146 essive function and reduced the emergence of tumor-specific Foxp3(+)CD4(+) regulatory T cells.

147 me alternative splicing factors could affect tumor-specific gene expression by binding to target gene

148 ferential histone enrichment associated with tumor-specific gene expression variation, sites of HPV i

149 spuriously magnify the extent of documented tumor-specific gene expression.

150 Targeted cancer therapeutics aim to exploit tumor-specific, genetic vulnerabilities specifically aff

151 rization) in glioma and the analysis of this tumor-specific HuR protein multimerization in clinical b

152 resulted in a significantly higher number of tumor-specific IFN-gamma-secreting immune cells compared

153 RR-S-Ac3 ManNAz is promising for research in tumor-specific imaging or drug delivery.

154 ieve selective background quenching and high tumor-specific imaging.

155 block immune regulatory pathways to enhance tumor-specific immune responses for the treatment of can

156 for lymphoma cells and its ability to induce tumor-specific immune responses, 11 has the potential to

157 mor-derived heat shock proteins can generate tumor-specific immune responses.

158 PD-1, CD279), resulting in dis-inhibition of tumor-specific immune responses.

159 ion, and infiltration, resulting in enhanced tumor-specific immune-mediated tumor regressions in prim

160 ting programmed cell death 1 (PD-1) activate tumor-specific immunity and have shown remarkable effica

161 gemcitabine and an agonist of CD40 to induce tumor-specific immunity mediated by T cells.

162 ults in direct tumor cell death and augments tumor-specific immunity, which enhances tumor control bo

163 ), eliminate various large tumors and induce tumor-specific immunity.

164 ctive mutant Fc domains behaved similarly to tumor-specific immunocytokine.

165 utations for their potential to act as early tumor-specific, immunogenic epitopes in expanding releva

166 An effective, nontoxic, tumor-specific immunotherapy is the ultimate goal in the

167 leled opportunity to subvert CMV antigens as tumor-specific immunotherapy targets.

168 Following ACT treatment, a significant and tumor specific increase in the uptake of a co-administer

169 he reduced response to IFN should facilitate tumor-specific infection in vivo.

170 photoactivation could be shown by using the tumor-specific, integrin-targeting (90)Y-DOTA-RGD and th

171 Our study provides an approach that targets tumor-specific intracellular antigens without using cell

172 To target this tumor-specific IQGAP requirement in vivo, we engineered

173 Tumor-specific ligands can further facilitate targeting

174 t on increasing the number of high affinity, tumor-specific ligands.

175 IFN-beta to the tumor microenvironment using tumor-specific mAbs can facilitate antitumor immunity, w

176 tion of the extrinsic apoptosis pathway in a tumor-specific manner by binding to and trimerizing its

177 e mutant antigens are usually expressed in a tumor-specific manner, aberrantly expressed antigens are

178 noma (SCC) and has been identified as a good tumor-specific marker for clinical staging of cervical s

179 ip) to capture CTC clusters independently of tumor-specific markers from unprocessed blood.

180 hed tumors in most animals associated with a tumor-specific memory T-cell response.

181 s who underwent total mesorectal excision or tumor-specific mesorectal excision for rectal cancer bet

182 It is the key technique for developing tumor-specific metabolic precursors that can generate un

183 ther uncovered that most previously reported tumor-specific methylation events are normally present i

184 We concluded that entropy is a tumor-specific metric only if confounding factors are co

185 oma cells (PDACs), drives the formation of a tumor-specific microenvironment.

186 l involvement, which makes capturing precise tumor-specific molecular information difficult.

187 tudy the biology of ovarian cancer, identify tumor-specific molecular markers, and develop novel trea

188 Tumor-specific molecules are needed across diverse areas

189 ormal tissues hold the potential of yielding tumor-specific molecules, but because the data are new t

190 e CD47-SIRPalpha interaction synergizes with tumor-specific monoclonal antibodies to eliminate human

191 Velcro-CD47 synergizes with tumor-specific monoclonal antibodies to enhance macropha

192 Detection of lymphocytes that target tumor-specific mutant neoantigens--derived from products

193 (HTS) has been used successfully to discover tumor-specific mutant peptides (neoantigens) from somati

194 Tumor-specific mutant peptides can be detected by the im

195 C class I-restricted epitopes, which carry a tumor-specific mutation resulting in improved MHC bindin

196 d by considering both germline genotypes and tumor specific mutations and expression profiles related

197 However, it is also important to identify tumor specific mutations that may determine response to

198 These tumor-specific mutations alter UPF1 RNA splicing and per

199 This study led to the discovery of tumor-specific mutations in PPM1D, encoding wild-type p5

200 Tumor-specific mutations were detectable in the cyst flu

201 c neoantigens that arise as a consequence of tumor-specific mutations, and emerging data suggest that

202 es that are regulated by MYC, explaining why tumor-specific MYC levels induce specific gene expressio

203 It induces tumor-specific necrosis by selectively disrupting redox

204 Tumor-specific neo-antigens that arise as a consequence

205 To investigate the roles of tumor-specific neoantigens and alterations in the tumor

206 accines improving the immune response toward tumor-specific neoantigens.

207 to higher frequency of somatic mutations and tumor-specific neoantigens.

208 indings suggest that despite the presence of tumor specific neoepitopes, T cell activation is activel

209 nce our capability to therapeutically target tumor-specific networks.

210 ment, with a special emphasis on the role of tumor-specific oncometabolites.

211 e topmost 5% (n = 33) ranked based on having tumor-specific or highly restricted normal tissue expres

212 Tumor-specific PARD3 alterations were found in 8% of LSC

213 data, network models can identify common or tumor specific pathway-level changes.

214 D, a tumor-penetrating peptide, for improved tumor-specific penetration of intraperitoneal compounds

215 rt hairpin RNA (shRNA) adjuvants, as well as tumor-specific peptide neoantigens into antigen presenti

216 also the antitumor therapeutic activity of a tumor-specific peptide vaccine.

217 onstruct the altered signaling pathways from tumor-specific phosphoproteomic data and known protein-p

218 Individualized tumor-specific primer panels of aberrant chromosomal jun

219 inescence and fluorescence imaging confirmed tumor-specific probe accumulation consistent with MSOT i

220 mputational modeling can be used to identify tumor-specific properties that influence the response to

221 This investigation tests the feasibility of tumor-specific prostate brachytherapy achievable with Yb

222 ovide strong evidence for the feasibility of tumor-specific prostate brachytherapy with Yb-169 and gG

223 ctivation of the protoxin using a tissue- or tumor-specific protease, such as PSA, can promote furthe

224 lop a network-based strategy for identifying tumor specific proteins and pathways that were predicted

225 These tumor-specific proteins have high clinical validity and

226 Tumor-specific pyruvate kinase M2 (PKM2) is instrumental

227 Here, the authors develop a tumor-specific quantum dot system that permits in vivo c

228 rgeting the broad tumor habitats rather than tumor-specific receptors, this strategy has the potentia

229 We did not observe de novo induction of tumor-specific regulatory T cells.

230 ate personalized ICBT strategies that target tumor-specific resistance mechanisms.

231 1 signaling potentiates epitope spreading in tumor-specific responses, a finding with clear implicati

232 Here we demonstrate a novel and tumor-specific role for aberrant Gli1 in the regulation

233 estigated the ability of CD4 cells to target tumor-specific self-antigens modified by citrullination,

234 e of FIP family members, such as FIP1C, in a tumor-specific setting remains elusive.

235 of-heterozygosity (the first three also in a tumor-specific setting).

236 er tumor-to-background contrast and stronger tumor-specific signal intensity in all tested tumor mode

237 enches excess quantum dots, leaving a highly tumor-specific signal provided by the intact quantum dot

238 e background quenching to gain exceptionally tumor-specific signals.

239 ch, however, is constrained by the rarity of tumor-specific single antigens.

240 Fifty tumor-specific single-nucleotide variations, including K

241 table system has been developed that enables tumor-specific singlet oxygen ((1) O2 ) generation for c

242 mutations may be valuable for increasing the tumor-specific spreading of retargeted oncolytic HSV vec

243 urthermore, it should preferably not rely on tumor-specific surface markers, as these are only availa

244 ratio (HR), 2.856; 1.314-6.207; P = 0.008], tumor-specific survival (HR, 8.336; 2.734-25.418; P < 0.

245 mor-activatable minicircles that use the pan-tumor-specific Survivin promoter to drive expression of

246 Peripheral tumor-specific T cell responses against main SCC-derived

247 Tumor-specific T cell responses are strongly impaired in

248 e hypothesized that functional impairment of tumor-specific T cell responses due to calcineurin inhib

249 ant patients showed lower IT infiltrates and tumor-specific T cell responses than NoKT-SCC, and intra

250 nt increase in FOXP3 + Treg cell numbers and tumor-specific T cell responses were observed, reaching

251 Tumor-specific T cell responses were significantly lower

252 ransfer of natural or genetically engineered tumor-specific T cells and discusses new strategies that

253 timately increase the frequency of activated tumor-specific T cells are currently being explored.

254 de promoted the selective differentiation of tumor-specific T cells bearing TCRs with high TCR/CD8:pM

255 body (mAb) treatment increased the number of tumor-specific T cells in the periphery and enhanced the

256 Although tumor-specific T cells recognize cancer cells, they are

257 ly predicted the function of large panels of tumor-specific T cells that were isolated prospectively

258 Reprogramming tumor-specific T cells through enforced expression of PG

259 owed the rapid production of high numbers of tumor-specific T cells, with optimal TCR expression and

260 ion of dendritic cells to present antigen to tumor-specific T cells.

261 trigger the innate immune system to activate tumor-specific T cells.

262 s act as helper cells to prime or reactivate tumor-specific T cells.

263 genesis, induced by chronic Akt signaling in tumor-specific T cells.

264 A expression to prospectively identify human tumor-specific T effector clones capable of engraftment

265 acquiring sufficient numbers of host-derived tumor-specific T lymphocytes by selection and expansion

266 dentified effective interventions to unleash tumor-specific T-cell activity in patients who naturally

267 er with others, have previously demonstrated tumor-specific T-cell dysfunction in the allogeneic envi

268 However, identifying tumor-specific T-cell epitopes is a major challenge.

269 progression-free survival by inducing robust tumor-specific T-cell immunity.

270 CD5-2 administration also enhanced tumor-specific T-cell infiltration and spatially redistr

271 high transduction, and therapeutic efficacy, tumor specific targeting and antiviral immune response s

272 Tumor-specific targeting ligands were recently exploited

273 EG) units, redox-sensitive cross-linker, and tumor-specific targeting ligands were synthesized to sel

274 eir stability, and lactobionic acid (LA) for tumor-specific targeting.

275 rimary challenge to the field is to identify tumor-specific targets to avoid off-tumor, on-target tox

276 beta genes, followed by the introduction of tumor-specific TCR genes, and that proved safer and more

277 owed by the transfer of genes encoding for a tumor-specific TCR.

278 Recent studies have shown that tumor-specific TCRs can be transduced into normal PBLs,

279 ally, a concurrent activation of spontaneous tumor-specific Th1 immunity also occurred.

280 Cancer eradication mediated by tumor-specific Th2 cells did not require B cells, natura

281 reported with IFNgamma-producing Th1 cells, tumor-specific Th2 cells have been largely neglected for

282 Thus, ACT with tumor-specific Th2 cells may represent a highly efficien

283 radication may be achieved by induction of a tumor-specific Th2 inflammatory immune response at the t

284 ndrical diffuser fiber successfully achieved tumor-specific thermal ablation, showing promising evide

285 Fully-human and tumor-specific, these antibodies are candidates for furt

286 data comprise the first molecular profile of tumor-specific TIL that are naturally responding and rep

287 PD-1 allows identification and isolation of tumor-specific TILs without previous knowledge of their

288 ecific PET/CT tracers, such as (18)F-NaF, or tumor-specific tracers, such as (18)F-FDG, although thes

289 Clinical data including laboratory values, tumor-specific treatment and outcome data were prospecti

290 can improve the target selection process for tumor specific treatments.

291 mechanisms behind the observed increased and tumor specific uptake are not fully elucidated, it is de

292 nt was shown to facilitate local release and tumor specific uptake.

293 Prolonged tumor-specific uptake demonstrated by [(18)F]24, which d

294 ion of a PI3Kdelta-specific inhibitor with a tumor-specific vaccine decreased numbers of suppressive

295 of laser-assisted intradermal delivery of a tumor-specific vaccine targeting XCR1(+) DCs to human ca

296 ed the TCR:pMHC dissociation rates (koff) of tumor-specific vaccine-induced CD8 T cell clones (n = 13

297 Analysis has concentrated on detecting tumor-specific variants, but recognition of germline var

298 PTPRU, and TNS1, of which INSR emerged as a tumor-specific vessel marker.

299 of cancer research is the identification of tumor-specific vulnerabilities that can be exploited for

300 cts in other DNA repair mechanisms provide a tumor specific way to kill cancer cells.